[{"id":"239cfbfd-4502-4f5e-a5da-4b96cfe72590","acronym":"","url":"https://clinicaltrials.gov/study/NCT07498400","created_at":"2026-04-04T01:40:42.252Z","updated_at":"2026-04-04T01:40:42.252Z","phase":"","brief_title":"Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer","source_id_and_acronym":"NCT07498400","lead_sponsor":"Xijing Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2026-03-27"},{"id":"15523e72-2092-4615-84e9-c8dac7362a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07484087","created_at":"2026-03-28T01:36:33.328Z","updated_at":"2026-03-28T01:36:33.328Z","phase":"","brief_title":"Ablation Compare With Surgery for Early Breast Cancer","source_id_and_acronym":"NCT07484087","lead_sponsor":"Peking University People's Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + AR positive + ER positive"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2026-03-19"},{"id":"09a2d6c3-0189-486e-8048-e063641e4790","acronym":"","url":"https://clinicaltrials.gov/study/NCT07480694","created_at":"2026-03-28T01:39:28.152Z","updated_at":"2026-03-28T01:39:28.152Z","phase":"","brief_title":"Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","source_id_and_acronym":"NCT07480694","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2026-03-18"},{"id":"855e0615-efe8-444c-a20c-79fd80778922","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475923","created_at":"2026-03-28T01:38:45.775Z","updated_at":"2026-03-28T01:38:45.775Z","phase":"","brief_title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","source_id_and_acronym":"NCT07475923","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/26/2026","start_date":" 08/26/2026","primary_txt":" Primary completion: 12/31/2031","primary_completion_date":" 12/31/2031","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2026-03-17"},{"id":"b06c4a15-488d-4c26-b536-d32ff1360c20","acronym":"EINSTEIN-TNBC","url":"https://clinicaltrials.gov/study/NCT07478705","created_at":"2026-03-28T01:41:18.017Z","updated_at":"2026-03-28T01:41:18.017Z","phase":"","brief_title":"Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","source_id_and_acronym":"NCT07478705 - EINSTEIN-TNBC","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2026-03-17"},{"id":"85d00d86-52dd-4bea-8f18-fb91850677e6","acronym":"STEPS-BC","url":"https://clinicaltrials.gov/study/NCT07474090","created_at":"2026-03-28T01:42:32.996Z","updated_at":"2026-03-28T01:42:32.996Z","phase":"","brief_title":"Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial","source_id_and_acronym":"NCT07474090 - STEPS-BC","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/05/2026","start_date":" 07/05/2026","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2026-03-16"},{"id":"503fb49c-7f9c-44d3-9d06-e13901c0cc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471815","created_at":"2026-03-28T01:43:58.232Z","updated_at":"2026-03-28T01:43:58.232Z","phase":"Phase 2","brief_title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","source_id_and_acronym":"NCT07471815","lead_sponsor":"Harbin Medical University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/04/2026","start_date":" 03/04/2026","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2026-03-13"},{"id":"5d9e65c6-b900-41df-834e-6e18a16cdf9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470203","created_at":"2026-03-28T01:44:18.552Z","updated_at":"2026-03-28T01:44:18.552Z","phase":"","brief_title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT07470203","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/31/2026","start_date":" 03/31/2026","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2026-03-13"},{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"dddae553-9ce4-4728-9047-032010347ec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471776","created_at":"2026-03-28T01:44:37.396Z","updated_at":"2026-03-28T01:44:37.396Z","phase":"Phase 2","brief_title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","source_id_and_acronym":"NCT07471776","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/11/2026","start_date":" 03/11/2026","primary_txt":" Primary completion: 03/11/2028","primary_completion_date":" 03/11/2028","study_txt":" Completion: 03/11/2029","study_completion_date":" 03/11/2029","last_update_posted":"2026-03-13"},{"id":"fd4f177e-f85d-440b-907a-20a6e87e3329","acronym":"PRO-ACTIVE","url":"https://clinicaltrials.gov/study/NCT07469709","created_at":"2026-03-28T01:44:12.315Z","updated_at":"2026-03-28T01:44:12.315Z","phase":"","brief_title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","source_id_and_acronym":"NCT07469709 - PRO-ACTIVE","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 850","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"11f1db6a-6822-4ad4-9456-501ec049e598","acronym":"BEND-MBEC","url":"https://clinicaltrials.gov/study/NCT07189702","created_at":"2025-09-27T08:41:02.423Z","updated_at":"2025-09-27T08:41:02.423Z","phase":"","brief_title":"Plant-Based Nutrition for Breast or Endometrial Cancer","source_id_and_acronym":"NCT07189702 - BEND-MBEC","lead_sponsor":"University of Rochester","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-09-24"},{"id":"df568c08-818e-4e88-a7ec-38377deb4c56","acronym":"","url":"https://clinicaltrials.gov/study/NCT07162051","created_at":"2025-09-13T08:42:14.196Z","updated_at":"2025-09-13T08:42:14.196Z","phase":"Phase 2","brief_title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT07162051","lead_sponsor":"Xijing Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-09-09"},{"id":"264b6c87-54a5-4e3b-9928-8b444e1c65f6","acronym":"ROYAL","url":"https://clinicaltrials.gov/study/NCT07151911","created_at":"2025-09-06T13:40:25.560Z","updated_at":"2025-09-06T13:40:25.560Z","phase":"","brief_title":"Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients","source_id_and_acronym":"NCT07151911 - ROYAL","lead_sponsor":"Azienda Ospedaliero-Universitaria di Modena","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2025-09-03"},{"id":"d967b5ae-d88b-4ec0-a06f-cb86153c285e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07133685","created_at":"2025-08-23T13:29:45.512Z","updated_at":"2025-08-23T13:29:45.512Z","phase":"","brief_title":"Evaluation of Serum IL-7 as a Biomarker in Breast Cancer","source_id_and_acronym":"NCT07133685","lead_sponsor":"Assiut University","biomarkers":" IL7","pipe":"","alterations":" ","tags":["IL7"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-08-21"},{"id":"e6296b14-457a-49ec-b305-921eba77b4de","acronym":"","url":"https://clinicaltrials.gov/study/NCT07088588","created_at":"2025-08-02T14:24:39.476Z","updated_at":"2025-08-02T14:24:39.476Z","phase":"Phase 1","brief_title":"Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07088588","lead_sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-07-28"},{"id":"f5ce8c06-3250-40ff-b25a-dd3430d92b46","acronym":"","url":"https://clinicaltrials.gov/study/NCT07078604","created_at":"2025-07-26T13:31:46.938Z","updated_at":"2025-07-26T13:31:46.938Z","phase":"Phase 2","brief_title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT07078604","lead_sponsor":"University of Washington","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-07-22"},{"id":"9c04029e-53f3-4765-aabc-f5bfc4bb5b40","acronym":"STAR-BREAST","url":"https://clinicaltrials.gov/study/NCT07070128","created_at":"2025-07-19T13:22:16.635Z","updated_at":"2025-07-19T13:22:16.635Z","phase":"","brief_title":"Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer","source_id_and_acronym":"NCT07070128 - STAR-BREAST","lead_sponsor":"AstraZeneca","biomarkers":" BRCA2","pipe":"","alterations":" ","tags":["BRCA2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 05/30/2026","primary_completion_date":" 05/30/2026","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2025-07-17"},{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"f3a57e99-36b8-4856-b1b8-be1b041c0803","acronym":"","url":"https://clinicaltrials.gov/study/NCT07048847","created_at":"2025-07-05T13:56:07.976Z","updated_at":"2025-07-05T13:56:07.976Z","phase":"","brief_title":"The Effect of Aerobic Exercise on Selective Biomarkers of Patients With Cancer","source_id_and_acronym":"NCT07048847","lead_sponsor":"Izmir Bakircay University","biomarkers":" LEP","pipe":"","alterations":" ","tags":["LEP"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 08/15/2023","primary_completion_date":" 08/15/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2025-07-03"},{"id":"2451850f-5b0c-4c08-aeda-4faec51709a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045311","created_at":"2025-07-05T13:59:45.588Z","updated_at":"2025-07-05T13:59:45.588Z","phase":"Phase 2","brief_title":"JS207 Combination Therapy in Triple-negative Breast Cancer","source_id_and_acronym":"NCT07045311","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • bulumtatug fuvedotin (9MW2821)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2029","study_completion_date":" 03/22/2029","last_update_posted":"2025-07-01"},{"id":"41e9d17f-953a-4dba-af2f-1c2f8cab199a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06905561","created_at":"2025-06-07T14:12:34.198Z","updated_at":"2025-06-07T14:12:34.198Z","phase":"","brief_title":"Topical Diclofenac for Prevention of Radiation-induced Dermatitis","source_id_and_acronym":"NCT06905561","lead_sponsor":"The Second Affiliated Hospital of Hainan Medical University","biomarkers":" IL4","pipe":"","alterations":" ","tags":["IL4"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 02/13/2025","start_date":" 02/13/2025","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-06-06"},{"id":"d7a65642-897e-45bd-94d5-4d6f95fb2fdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856499","created_at":"2025-06-07T14:55:53.232Z","updated_at":"2025-06-07T14:55:53.232Z","phase":"Phase 1","brief_title":"Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT06856499","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cirtuvivint (SM08502)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-05-28"},{"id":"4a3ee118-a60f-43d4-9eb9-1692c44ffa53","acronym":"EXIGENCE","url":"https://clinicaltrials.gov/study/NCT06962163","created_at":"2025-09-07T01:31:13.362Z","updated_at":"2025-09-07T01:31:13.362Z","phase":"","brief_title":"Prospective Study, Assessing Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT06962163 - EXIGENCE","lead_sponsor":"Institut Cancerologie de l'Ouest","biomarkers":" CXCR4","pipe":"","alterations":" ","tags":["CXCR4"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2025-05-20"}]